ADAMTS13 단백질 변형체 및 그것의 용도

• Main Authors: ERCIG BOGAC, VOORBERG JOHANNES JACOBUS, GOMES GRACA NUNO ALEXANDRE
• Format: Patent
• Language: Korean
• Published: 21.03.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

본 발명은 ADAMTS13의 잔기 1 내지 685를 포함하는 ADAMTS13 단백질 변형체에 관한 것으로서, 상기 변형체에서 야생형 ADAMTS13 대비 하나 이상의 N-연결 글리코실화 부위가 추가 및/또는 야생형 ADAMTS13 대비 하나 이상의 기 존재 N-연결 글리코실화 부위가 이동한다. 본 발명은 또한 이러한 ADAMTS13 변형체를 포함하는 조성물과 그것의 제조방법과 그것의 용도, 특히 항혈전제로의 용도, 그리고 혈전성 질병, 혈전성 미세혈관증, 혈전성 혈소판 감소 자반증(thrombotic thrombocytopenic purpura, TTP), 용혈성 요독증(hemolytic-uremic syndrome, HUS), 허혈성 뇌졸중, 전신성 색전증, COVID19, 항인지질 증후군, 전자간증(pre-eclampsia)/HELLP 증후군, 패혈증, 낫모양 적혈구증(sickle cell disease)의 치료용도에 대한 것이다. The invention relates to ADAMTS13 protein variants comprising residues 1 to 685 of ADAMTS13 and wherein one or more N-linked glycosylation sites are added as compared to wild-type ADAMTS13 and/or one or more existing N-linked glycosylation sites are shifted as compared to wild-type ADAMTS13. The invention further relates to compositions comprising such ADAMTS13 variants, methods for their preparation and uses thereof, in particular as an antithrombotic agent, and in the treatment of thrombotic disease, thrombotic microangiopathy, thrombotic thrombocytopenic purpura (TTP), hemolytic-uremic syndrome (HUS), ischemic stroke, systemic thrombosis, COVID19, antiphospholipid syndrome, pre-eclampsia/HELLP syndrome, sepsis and sickle cell disease.